Medication-Induced Sexual Side Effects
Beta-blockers, SSRIs, finasteride, antipsychotics, and more
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Class-dependent; effects are labeled adverse events, not approvals
Reference only. Not medical advice.
What can go wrong
Sexual side effects drive nonadherence to important medications, so the goal is balance, not blanket avoidance, never stop a prescribed drug abruptly to chase sexual recovery. Strategies include dose adjustment, switching within or across classes (e.g., to a prolactin-sparing antipsychotic or a different antidepressant), timing changes, and treating comorbid causes. The persistence of symptoms after stopping finasteride (post-finasteride syndrome) or SSRIs (post-SSRI sexual dysfunction) is reported but contested and incompletely understood.
This is something to take to a clinician. The Atlas can tell you what is known about medication-induced sexual side effects in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
A wide range of common medications impair sexual function across libido, erection, ejaculation, and orgasm. SSRIs are among the worst offenders, with reported sexual side-effect rates spanning roughly 25% to nearly 90% depending on agent and how it is measured (paroxetine and escitalopram are often cited as higher-risk). Antipsychotics that raise prolactin (first-generation agents, risperidone, paliperidone) cause dysfunction in an estimated 30-60% of patients. Beta-blockers and finasteride are also implicated. Many of these effects are reversible with medication review, but finasteride and SSRIs are linked to debated persistent syndromes.
When the prescription, not the patient, is the cause.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Mechanisms differ by class. SSRIs raise serotonergic tone, which blunts desire and orgasm and delays ejaculation. Prolactin-elevating antipsychotics (via dopamine D2 blockade) lower libido and impair arousal; some second-generation agents (quetiapine, aripiprazole, clozapine) are more prolactin-sparing. Beta-blockers may reduce arousal and erectile function through central and peripheral effects. Finasteride, a 5-alpha-reductase inhibitor, lowers dihydrotestosterone and is associated with erectile, libido, and ejaculatory complaints.
Safety in detail
Do not start, stop, or change doses of antidepressants, antipsychotics, beta-blockers, or finasteride without physician guidance. Medication adjustments to address sexual side effects require evaluation and monitoring by a qualified clinician.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Prolactin level when antipsychotic-related dysfunction is suspected
- Mood and psychiatric stability during any antidepressant or antipsychotic change
- Blood pressure and cardiac status when adjusting beta-blockers
- Sexual-function reassessment after any medication change
What people get wrong
Often saidIf a drug causes sexual side effects, just stop taking it
ActuallyAbruptly stopping antidepressants, antipsychotics, or cardiac drugs can be dangerous. Effects are often managed by dose change or switching under medical supervision.
Often saidAll antidepressants and antipsychotics affect sex equally
ActuallyThey do not, risk varies widely by agent. Some SSRIs and prolactin-sparing antipsychotics are notably less likely to cause problems.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- SSRI sexual side effects
- ~25% to ~89% (agent- and method-dependent)
- Higher-risk SSRIs
- Paroxetine, escitalopram (commonly cited)
- Prolactin-raising antipsychotics
- Dysfunction in ~30-60%
- Persistent syndromes (debated)
- PSSD (post-SSRI), PFS (post-finasteride)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Medication-Induced Sexual Side Effects. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Reviews of SSRI-associated sexual dysfunctionvarious
Report prevalence ranging from about 25% to nearly 90% depending on the agent and assessment method, with paroxetine and escitalopram often higher-risk
Antipsychotic hyperprolactinemia literaturevarious
Estimate sexual dysfunction in roughly 30-60% of patients on potent dopamine-blocking agents, with prolactin elevation a key driver